Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Radiochemotherapy, Radioimmunotherapy and Targeted Therapy in Locally Advanced and Metastatic...
share announcement

Radiochemotherapy, Radioimmunotherapy and Targeted Therapy in Locally Advanced and Metastatic Head and Neck Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (20 September 2024) | Viewed by 3220

Special Issue Editor

Dr. Lianghao Ding

E-Mail Website
Guest Editor
Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA
Interests: cancer genomics; radiation oncology; precision medicine; head and neck cancer; liver cancer; circulating miRNA

Special Issue Information

Dear Colleagues,

Locally advanced head and neck cancer presents complex challenges for cancer management and significantly affects the overall survival rates of patients. Radiochemotherapy is the standard treatment modality for this type of cancer, either as a post-surgery adjuvant therapy or definitive therapy for non-operable tumors. In this Special Issue, we will examine the latest advancements in clinical research, cancer biology and precision medicine, all with the goal of achieving improved tumor eradication and minimizing toxicities associated with radiochemotherapy. We will also review the progress of targeted therapy and emerging immunotherapy with checkpoint inhibitors, particularly when used in combination with radiotherapy.

Dr. Lianghao Ding
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • HNSCC
  • radiochemotherapy
  • radiotherapy targeted therapy
  • immunotherapy
  • precision medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1006 KiB  
Article
Palliative Quad Shot Radiation Therapy with or without Concurrent Immune Checkpoint Inhibition for Head and Neck Cancer
by Rituraj Upadhyay, Emile Gogineni, Glenis Tocaj, Sung J. Ma, Marcelo Bonomi, Priyanka Bhateja, David J. Konieczkowski, Sujith Baliga, Darrion L. Mitchell, Sachin R. Jhawar, Simeng Zhu, John C. Grecula, Khaled Dibs, Mauricio E. Gamez and Dukagjin M. Blakaj
Cancers 2024, 16(5), 1049; https://doi.org/10.3390/cancers16051049 - 5 Mar 2024
Viewed by 2746
Abstract
Objectives: Patients with recurrent and metastatic head and neck cancer (HNC) have limited treatment options. ‘QuadShot’ (QS), a hypofractionated palliative radiotherapy regimen, can provide symptomatic relief and local control and may potentiate the effects of immune checkpoint inhibitors (ICIs). We compared outcomes of [...] Read more.
Objectives: Patients with recurrent and metastatic head and neck cancer (HNC) have limited treatment options. ‘QuadShot’ (QS), a hypofractionated palliative radiotherapy regimen, can provide symptomatic relief and local control and may potentiate the effects of immune checkpoint inhibitors (ICIs). We compared outcomes of QS ± concurrent ICIs in the palliative treatment of HNC. Materials and Methods: We identified patients who received ≥three cycles of QS from 2017 to 2022 and excluded patients without post-treatment clinical evaluation or imaging. Outcomes for patients who received QS alone were compared to those treated with ICI concurrent with QS, defined as receipt of ICI within 4 weeks of QS. Results: Seventy patients were included, of whom 57% received concurrent ICI. Median age was 65.5 years (interquartile range [IQR]: 57.9–77.8), and 50% patients had received prior radiation to a median dose of 66 Gy (IQR: 60–70). Median follow-up was 8.8 months. Local control was significantly higher with concurrent ICIs (12-month: 85% vs. 63%, p = 0.038). Distant control (12-month: 56% vs. 63%, p = 0.629) and median overall survival (9.0 vs. 10.0 months, p = 0.850) were similar between the two groups. On multivariable analysis, concurrent ICI was a significant predictor of local control (HR for local failure: 0.238; 95% CI: 0.073–0.778; p = 0.018). Overall, 23% patients experienced grade 3 toxicities, which was similar between the two groups. Conclusions: The combination of QS with concurrent ICIs was well tolerated and significantly improved local control compared to QS alone. The median OS of 9.4 months compares favorably to historical controls for patients with HNC treated with QS. This approach represents a promising treatment option for patients with HNC unsuited for curative-intent treatment and warrants prospective evaluation. Full article
(This article belongs to the Special Issue Radiochemotherapy, Radioimmunotherapy and Targeted Therapy in Locally Advanced and Metastatic Head and Neck Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop